Industry overview; Cancer Drugs & Treatments Market policy and plan, product specification, manufacturing process and cost structure 2023

Press Release   •   Oct 25, 2016 16:58 EDT

The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’

Global cancer drugs and treatments market will reach $143.7bn by 2023. 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ explains just how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make specific long term plans. Don’t let your competitors get the head-start on you, order this report today.

Check Complete Report @

Have you seen the recent news on Cancer Drugs?

  • Merck’s new cancer drug kept more than 4 of 5 melanoma patients alive for a year
  • Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes
  • EU approval for Bayer’s prostate cancer drug
  • Sanofi ditches late-stage bone marrow cancer drug

The Anti-cancer treatment market is already worth $77.4bn (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development – can you afford not to be involved? Should you and your company be capturing a greater market share?

Essential facts examined in this report

  • Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology.
  • Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy.
  • Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects.

Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this report.

Get Sample Brochure of the Report @

Discover exactly what the industry leaders are doing TODAY

'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade.

Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? – ONLY THIS


  • •Rituxan
  • •Herceptin
  • •Avastin
  • •Gleevec
  • •Revlimid
  • •Alimta
  • •Velcade

PLUS – In-depth country analysis – Discover which countries and regions will drive the oncology drugs market to 2023?

The US spent $322bn on healthcare in 2011, GMR Data estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012.

But how will these country’s markets develop? This report will tell you - TODAY

Exclusive Industry sourced information, not available anywhere else

As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

With over 240+ pages, and over 270+ charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

Order a copy of Cancer Drugs & Treatments Market Report now @

About us:

MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.

MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.

MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Contact us:
Mayur S
Sales Manager

2711 Centerville Road, Suite 400,
Telephone: 1-302-261-5343